Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

被引:0
|
作者
Kaser, A [1 ]
Enrich, B [1 ]
Ludwiczek, O [1 ]
Vogel, W [1 ]
Tilg, H [1 ]
机构
[1] Univ Innsbruck Hosp, Dept Med, Div Gastroenterol & Hepatol, A-6020 Innsbruck, Austria
关键词
interferon-alpha; hepatitis C infection; cytotoxicity; perforin; Fas ligand;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cell-mediated cytotoxicity is exerted via perforin and Fas ligand (FasL). We have recently shown that IFN-alpha up-regulates Fast expression in T cells isolated from healthy volunteers and augments activation-induced T cell death. Since the Fas/FasL system is implicated in the pathogenesis of hepatic failure and both molecules have been shown to be up-regulated in hepatitis C virus (HCV) infection, we studied whether cytotoxicity via the Fast system is enhanced by IFN-alpha and therefore could contribute to hepatic injury. We investigated Fast and perforin expression in peripheral blood mononuclear cells (PBMC) derived from HCV+ donors by Northern analysis and soluble Fast synthesis by ELISA. Natural killer (NK) cell and cytotoxic T lymphocyte (CTL) cytotoxicity was studied by Cr-51-release assays. IFN-alpha up-regulates Fast mRNA and protein synthesis in mitogen-activated PBMC of HCV+ individuals, as previously found in healthy subjects. Stimulation with IFN-alpha increases perforin mRNA levels in PBMC. In NK cytotoxicity assays, the enhancement of cytotoxicity by IFN-alpha is mainly due to the perforin pathway, while the Fast pathway plays only a minor role. In CTL cytotoxicity experiments neither the Fast nor the perforin pathway is further enhanced by IFN-alpha. Our data suggest that upregulation of perforin by IFN-alpha results in elevated cytotoxicity, suggesting that IFN-alpha might support elimination of virally infected cells via this pathway. In contrast, the major effect of IFN-alpha on the Fas/FasL system might be the enhanced elimination of activated T cells as a means of finally limiting a T cell response.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 50 条
  • [21] High initial dose combination regimen with interferon-alpha and ribavirin in chronic hepatitis C
    Kostev, I
    Ivanova, I
    Atanassova, M
    Atanassova, A
    Glinkova, V
    Gancheva, D
    Shalev, I
    Manevska, B
    Krasnaliev, I
    Tomcheva, S
    HEPATO-GASTROENTEROLOGY, 2003, 50 (50) : 463 - 466
  • [22] Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
    de Oliveira Andrade, Luis Jesuino
    Atta, Ajax Merces
    Brito de Sousa Atta, Maria Luiza
    Kalil Mangabeira, Celia Neder
    Parana, Raymundo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (04) : 377 - 381
  • [23] Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C
    Recasens, M
    Aguilera, E
    Ampurdanés, S
    Tapias, JMS
    Simó, O
    Casamitjana, R
    Conget, I
    DIABETIC MEDICINE, 2001, 18 (09) : 764 - 767
  • [24] Clinical correlations between chronic hepatitis C infection and decreasing bone mass density after treatment with interferon-alpha
    Vahid Babaei
    Masoud Ghorbani
    Nastaran Mohseni
    Hojjat Afraid
    Yassaman Saghaei
    Shahram Teimourian
    Asian Pacific Journal of Tropical Biomedicine, 2017, (02) : 161 - 165
  • [25] Fate of antibody to interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN alpha 2 and retreated with lymphoblastoid IFN alpha
    Antonelli, G
    Giannelli, G
    Currenti, M
    Simeoni, E
    Milella, M
    Schiraldi, O
    Dianzani, F
    INTERNATIONAL HEPATOLOGY COMMUNICATIONS, 1995, 4 (04): : 232 - 237
  • [26] LOSS OF HBSAG WITH INTERFERON-ALPHA THERAPY IN CHRONIC HEPATITIS-D VIRUS-INFECTION
    LAU, JYN
    KING, R
    TIBBS, CJ
    CATTERALL, AP
    SMITH, HM
    PORTMANN, BC
    ALEXANDER, GJM
    WILLIAMS, R
    JOURNAL OF MEDICAL VIROLOGY, 1993, 39 (04) : 292 - 296
  • [27] Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C - Relationship to genotypes of hepatitis C virus
    Izumi, N
    Enomoto, N
    Uchihara, M
    Murakami, T
    Ono, K
    Noguchi, O
    Miyake, S
    Nouchi, T
    Fujisawa, K
    Marumo, F
    Sato, C
    DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (05) : 989 - 994
  • [28] Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
    Kim, WR
    Poterucha, JJ
    Hermans, JE
    Therneau, TM
    Dickson, ER
    Evans, RW
    Gross, JB
    ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 866 - +
  • [29] Characteristics of Graves' Disease in a Cohort of Chronic Hepatitis C Patients Treated With Interferon-alpha and Ribavirin
    Tran, Huy A.
    Reeves, Glenn Em
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2011, 1 (01) : 14 - 20
  • [30] Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-alpha therapy
    Musset, L
    Ghillani, P
    Lunel, F
    Cacoub, P
    Cresta, P
    Frangeul, L
    Rosenheim, M
    Preudhomme, JL
    IMMUNOLOGY LETTERS, 1997, 55 (01) : 41 - 45